Report Type: Therapy Reports
Report Category: Gastrointestinal
Report Subcategory: Ulcerative Colitis
Price: 2999.00
Date: July 2021

Ulcerative Colitis: Global Market Landscape till 2030 - Epidemiology, Drugs, Trials, Technology, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, and Manufacturing

Ulcerative Colitis:
Ulcerative Colitis is a relapsing and remitting episodes of inflammatory condition of the mucosal layer of the digestive tract especially colon and rectum.

Top 50 Key Players:
Johnson & Johnson
F. Hoffmann-La Roche Ltd
Pfizer Inc
Novartis AG
Merck & Co Inc
GlaxoSmithKline Plc
Sanofi
Mitsubishi Chemical Holdings Corp
AbbVie Inc
Takeda Pharmaceutical Co Ltd
Bristol-Myers Squibb Co
AstraZeneca Plc
Amgen Inc
Gilead Sciences Inc
Eli Lilly and Co
Boehringer Ingelheim International GmbH
Teva Pharmaceutical Industries Ltd
Biogen Inc
Astellas Pharma Inc
Mylan NV
Bausch Health Companies Inc
Eisai Co Ltd
UCB SA
EBOS Group Ltd
Sino Biopharmaceutical Ltd
Mitsubishi Tanabe Pharma Corp
Shionogi & Co Ltd
Aspen Pharmacare Holdings Ltd
Endo International Plc
Humanwell Healthcare Group Co Ltd
Cipla Ltd
Cadila Healthcare Ltd
Vifor Pharma Ltd
Swedish Orphan Biovitrum AB
Glenmark Pharmaceuticals Ltd
Yuhan Corp
Torrent Pharmaceuticals Ltd
Daewoong Co Ltd
Alkem Laboratories Ltd
Mochida Pharmaceutical Co Ltd
Celltrion Inc
Esteve Pharmaceuticals SA
Chong Kun Dang Pharmaceutical Corp
Kaken Pharmaceutical Co Ltd
Zeria Pharmaceutical Co Ltd
Galapagos NV
Akebia Therapeutics Inc
Lexicon Pharmaceuticals Inc
GW Pharmaceuticals Plc
Theravance Biopharma Inc